Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Treeline logo — Making medicines at the highest level

Treeline

Making medicines at the highest level

Founded 2021 United States Watertown, United States 172 employees Series A Total: $473.27M Biotechnology, Health Care +1

General Information

Company Name Treeline
Founded Year 2021
Location United States Watertown, United States
Employees 172
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Series A
Business Model B2B, D2C, B2D
Revenue Model Product Sales, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Treeline. To contact Treeline, visit treeline.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Treeline compare?

A PDF of Treeline and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Treeline soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Treeline

Treeline, a privately held, clinical-stage biopharmaceutical company founded in 2021, carries the ambitious slogan: "Making medicines at the highest level." Operating across the United States and Europe, the company focuses on leveraging cutting-edge computational tools to match disease targets with proven drug approaches. By prioritizing the redefinition of treatment for cancer and other serious diseases, Treeline holds a promising place in the Biotechnology, Health Care, and Life Sciences industries.

Its leadership is comprised of seasoned experts in biology, chemistry, protein science, computation, and clinical development. This robust team attracted significant investor confidence, culminating in a substantial $261.27M Series A investment on 11 October 2022. Notable investors include Arch Venture Partners, OrbiMed, Access Industries, Rock Springs Capital, and Kohlberg Kravis Roberts, indicating a strong endorsement of Treeline's innovative approach and strategic value proposition in the healthcare sector.

Business keywords: biopharma, clinical-stage, precision medicine, oncology, cancer treatment, serious diseases, drug development, R&D, computational tools, biology, chemistry, protein science, clinical development, transformative medicine, disease targets

Services & Products

Medicine Development
Research and Development
Protein Target Analysis
Drug Candidate Design

Target Customers

Patients with Cancer Patients with Autoimmune Diseases Patients with Neurological Diseases

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $261.27M 5
Arch Venture Partners OrbiMed Access Industries
Arch Venture Partners, OrbiMed +3
11 Oct 2022
Series A $212.00M 5
Arch Venture Partners Casdin Capital GV
Arch Venture Partners, Casdin Capital +3
27 Apr 2021

Treeline Alternatives & Competitors

View All Alternatives
Treeline vs
Relay Therapeutics
Relay Therapeutics United States

Integrating leading-edge computational and experimental science to transform human health.

IPO
230 employees
Biotechnology, Health Care
Compare Treeline vs Relay Therapeutics
Treeline vs
Nimbus Therapeutics
Nimbus Therapeutics United States

We develop breakthrough medicines for patients through precision small molecule design.

103 employees
Biotechnology, Health Care
Compare Treeline vs Nimbus Therapeutics
Treeline vs
Redx Pharma
Redx Pharma United Kingdom

Biotech company focusing on the discovery and development of novel targeted medicines to treat cance...

Post-IPO Equity
39 employees
Biotechnology, Health Care
Compare Treeline vs Redx Pharma
View all alternatives

FAQ About Treeline

Making medicines at the highest level
Treeline was founded in 2021.
Treeline is headquartered in Watertown, United States.
Treeline operates in Biotechnology, Health Care and Life Sciences. Its work centres on biopharma, clinical-stage, precision medicine and oncology. Its customers include Patients with Cancer, Patients with Autoimmune Diseases and Patients with Neurological Diseases.
Treeline has a B2B, D2C and B2D business model. Its revenue comes from Product Sales and Licensing.
Treeline has approximately 172 employees.
Treeline has completed 2 funding rounds, raising a total of $473.27M. The latest funding stage is Series A.
Treeline offers: Medicine Development, Research and Development, Protein Target Analysis, Drug Candidate Design.
Top alternatives and competitors to Treeline include Relay Therapeutics, Nimbus Therapeutics, Redx Pharma, FogPharma, Ventus Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Treeline and Relay Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Treeline, https://bouncewatch.com/company/treeline-biosciences, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout